Literature DB >> 14642644

Memantine attenuates the increase in striatal preproenkephalin mRNA expression and development of haloperidol-induced persistent oral dyskinesias in rats.

Ole A Andreassen1, Jo Waage, Bente Finsen, Hugo A Jørgensen.   

Abstract

Tardive dyskinesia (TD) is a serious motor side effect of long-term neuroleptic treatment that may persist after drug withdrawal. Alterations in striatal enkephalinergic neurons due to excessive glutamatergic activity is a possible pathogenetic mechanism. We studied the effect of the NMDA antagonist memantine in a rat model of TD, in which vacuous chewing movements (VCM) were induced by 20 weeks of haloperidol administration. The striatal density of preproenkephalin mRNA was measured and the number of neurons estimated. Haloperidol induced persistent VCM that was associated with increased striatal expression of preproenkephalin mRNA. Memantine inhibited the development of haloperidol-induced persistent VCM and attenuated the increase in preproenkephalin mRNA expression. This suggests that glutamate-mediated up-regulation of striatal enkephalin plays a role in the development of haloperidol-induced persistent oral dyskinesias.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 14642644     DOI: 10.1016/j.brainres.2003.09.035

Source DB:  PubMed          Journal:  Brain Res        ISSN: 0006-8993            Impact factor:   3.252


  3 in total

Review 1.  N-Methyl-D-aspartate receptors as a target for improved antipsychotic agents: novel insights and clinical perspectives.

Authors:  Mark J Millan
Journal:  Psychopharmacology (Berl)       Date:  2005-03-10       Impact factor: 4.530

2.  Upregulation of dopamine D3, not D2, receptors correlates with tardive dyskinesia in a primate model.

Authors:  Souha Mahmoudi; Daniel Lévesque; Pierre J Blanchet
Journal:  Mov Disord       Date:  2014-05-16       Impact factor: 10.338

3.  Pharmacodynamics of memantine: an update.

Authors:  G Rammes; W Danysz; C G Parsons
Journal:  Curr Neuropharmacol       Date:  2008-03       Impact factor: 7.363

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.